WASHINGTON (AP) – A new kind of flu vaccine moved a step closer to the U.S.

Moderna's novel vaccine was at the center of dustup with agency earlier this year

Moderna flu vaccine faces a key FDA advisory panel review as analysts weigh approval odds, postmarketing study costs, and growth potential.

U.S. health advisers are debating a new kind of flu vaccine

Recommendation could pave the way for approval of the mRNA vaccine in adults 50 and up